XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss Per Share Attributable to Adaptive Biotechnologies Corporation Common Shareholders - Weighted-Average Common Stock Equivalents were Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 26,020,265 19,977,348 25,210,492 18,856,587
Common Stock Options Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 13,806,283 13,996,403 14,054,478 13,984,427
Nonvested Restricted Stock Units Outstanding        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 10,301,308 5,486,711 9,575,868 4,490,170
Nonvested Market-based Restricted Stock Units Outstanding Granted        
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]        
Antidilutive securities 1,912,674 494,234 1,580,146 381,990